Table I.
Patient characteristics.
| Characteristics | Value (%) |
|---|---|
| Total patients, n | 21 (100) |
| Gender, n | |
| Male | 17 (81.0) |
| Female | 4 (19.0) |
| Age, years | |
| Median | 65 |
| Range | 46–77 |
| ECOG PS, n | |
| 0 | 10 (47.6) |
| 1 | 4 (19.0) |
| 2 | 7 (33.3) |
| Creatinine clearance in ml/min, n | |
| 40–50 | 3 (14.3) |
| 51–60 | 4 (19.0) |
| 61–80 | 4 (19.0) |
| 81–90 | 5 (23.8) |
| ≥91 | 5 (23.8) |
| AUCa in mg/ml × min, n | |
| 2.5–3.0 | 2 (9.5) |
| 3.1–4.0 | 4 (19.0) |
| 4.1–4.5 | 5 (23.8) |
| 4.6–5.0 | 5 (23.8) |
| 5.1–6.0 | 4 (19.0) |
| ≥6.1 | 1 (4.8) |
| Histology, n | |
| Adenocarcinoma | 14 (66.7) |
| Squamous cell carcinoma | 3 (14.3) |
| Large-cell carcinoma | 2 (9.5) |
| Unspecified NSCLC | 2 (9.5) |
| Clinical stage, n | |
| IIIB | 5 (23.8) |
| IV | 16 (76.2) |
| No. of organs with metastases, n | |
| 0 (stage IIIB) | 5 (23.8) |
| 1 | 3 (14.3) |
| 2 | 6 (28.6) |
| ≥3 | 7 (33.3) |
a
AUC, vs. time curve, calculated by Calvert’s formula.
ECOG, Eastern Cooperative Oncology Group; AUC, area under curve; NSCLC, non-small cell lung cancer; PS, performance status.